Advertisement

Liver Diseases pp 197-204 | Cite as

Non-B, Non-C Viral Hepatitis

  • Hubert E. BlumEmail author
Chapter

Abstract

Non-B/non-C viral hepatitis can be caused by the three well characterized hepatotropic viruses: hepatitis A virus (HAV), hepatitis delta virus (HDV) and hepatitis E virus (HEV). Their epidemiology as well as their pathogenesis have been studied in great detail. Further, the structure and genetic organization of their RNA genomes including the viral life cycle have been elucidated. These discoveries have been successfully translated into important clinical applications, such as the specific diagnosis, therapy and prevention of the associated liver diseases, including acute or fulminant hepatitis as well as for chronic hepatitis D and E, respectively, their long-term sequelae liver cirrhosis and hepatocellular carcinoma (HCC).

Keywords

Hepatitis A Hepatitis D Hepatitis E 

Notes

Acknowledgments

Conflict of interests: The author declares no conflict of interest.

Financial disclosure: The author has no financing to disclose.

References

  1. 1.
    Feinstone SM, Kapikian AZ, Purceli RH. Hepatitis A: detection by immune electron microscopy of a viruslike antigen associated with acute illness. Science. 1973;182:1026–8.PubMedCrossRefPubMedCentralGoogle Scholar
  2. 2.
    Martin A, Lemon SM. Hepatitis A virus: from discovery to vaccines. Hepatology. 2006;43:S164–72.PubMedCrossRefPubMedCentralGoogle Scholar
  3. 3.
    Blumberg BS, Alter HJ, Visnich S. A “new” antigen in leukemia sera. JAMA. 1965;191:541–6.PubMedCrossRefPubMedCentralGoogle Scholar
  4. 4.
    Blumberg BS, Gerstley BJ, Hungerford DA, London WT, Sutnick AI. A serum antigen (Australia antigen) in Down’s syndrome, leukemia, and hepatitis. Ann Intern Med. 1967;66:924–31.PubMedCrossRefPubMedCentralGoogle Scholar
  5. 5.
    Prince AM. An antigen detected in the blood during the incubation period of serum hepatitis. Proc Natl Acad Sci U S A. 1968;60:814–21.PubMedPubMedCentralCrossRefGoogle Scholar
  6. 6.
    Prince AM. Relation of Australia and SH antigens. Lancet. 1968;2:462–3.PubMedCrossRefPubMedCentralGoogle Scholar
  7. 7.
    Rizzetto M, Canese MG, Arico S, Crivelli O, Trepo C, Bonino F, Verme G. Immunofluorescence detection of new antigen-antibody system (delta/anti-delta) associated to hepatitis B virus in liver and in serum of HBsAg carriers. Gut. 1977;18:997–1003.PubMedPubMedCentralCrossRefGoogle Scholar
  8. 8.
    Rizzetto M, Hoyer B, Canese MG, Shih JW, Purcell RH, Gerin JL. Delta agent: association of delta antigen with hepatitis B surface antigen and RNA in serum of delta-infected chimpanzees. Proc Natl Acad Sci U S A. 1980;77:6124–8.PubMedPubMedCentralCrossRefGoogle Scholar
  9. 9.
    Gupta DN, Smetana HF. The histopathology of viral hepatitis as seen in the Delhi epidemic (1955–56). Indian J Med Res. 1957;45:101–13.PubMedPubMedCentralGoogle Scholar
  10. 10.
    Balayan MS, Andjaparidze AG, Savinskaya SS, Ketiladze ES, Braginsky DM, Savinov AP, Poleschuk VF. Evidence for a virus in non-A, non-B hepatitis transmitted via the fecal-oral route. Intervirology. 1983;20:23–31.PubMedCrossRefPubMedCentralGoogle Scholar
  11. 11.
    Kane MA, Bradley DW, Shrestha SM, Maynard JE, Cook EH, Mishra RP, Joshi DD. Epidemic non-A, non-B hepatitis in Nepal. Recovery of a possible etiologic agent and transmission studies in marmosets. JAMA. 1984;252:3140–5.PubMedCrossRefPubMedCentralGoogle Scholar
  12. 12.
    Krawczynski K, Bradley DW. Enterically transmitted non-A, non-B hepatitis: identification of virus-associated antigen in experimentally infected cynomolgus macaques. J Infect Dis. 1989;159:1042–9.PubMedCrossRefPubMedCentralGoogle Scholar
  13. 13.
    Hoofnagle JH, Nelson KE, Purcell RH. Hepatitis E. N Engl J Med. 2012;367:1237–44.PubMedCrossRefPubMedCentralGoogle Scholar
  14. 14.
    Kamar N, Bendall R, Legrand-Abravanel F, Xia NS, Ijaz S, Izopet J, Dalton HR. Hepatitis E. Lancet. 2012;379:2477–88.PubMedCrossRefPubMedCentralGoogle Scholar
  15. 15.
    Jacobsen KH, Wiersma ST. Hepatitis A virus seroprevalence by age and world region, 1990 and 2005. Vaccine. 2010;28:6653–7.PubMedCrossRefPubMedCentralGoogle Scholar
  16. 16.
    Wasley A, Fiore A, Bell BP. Hepatitis A in the era of vaccination. Epidemiol Rev. 2006;28:101–11.PubMedCrossRefPubMedCentralGoogle Scholar
  17. 17.
    Wasley A, Samandari T, Bell BP. Incidence of hepatitis A in the United States in the era of vaccination. JAMA. 2005;294:194–201.PubMedCrossRefPubMedCentralGoogle Scholar
  18. 18.
    Advisory Committee on Immunization P, Fiore AE, Wasley A, Bell BP. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2006;55:1–23.Google Scholar
  19. 19.
    Wasley A, Grytdal S, Gallagher K. Centers for disease C, prevention. Surveillance for acute viral hepatitis—United States, 2006. MMWR Surveill Summ. 2008;57:1–24.PubMedPubMedCentralGoogle Scholar
  20. 20.
    Daniels D, Grytdal S, Wasley A. Centers for disease C, prevention. Surveillance for acute viral hepatitis – United States, 2007. MMWR Surveill Summ. 2009;58:1–27.PubMedPubMedCentralGoogle Scholar
  21. 21.
    Klevens RM, Miller JT, Iqbal K, Thomas A, Rizzo EM, Hanson H, Sweet K, et al. The evolving epidemiology of hepatitis a in the United States: incidence and molecular epidemiology from population-based surveillance, 2005–2007. Arch Intern Med. 2010;170:1811–8.PubMedCrossRefPubMedCentralGoogle Scholar
  22. 22.
    Rizzetto M, Ponzetto A, Forzani I. Hepatitis delta virus as a global health problem. Vaccine. 1990;8(Suppl):S10–4; discussion S21–13.PubMedCrossRefPubMedCentralGoogle Scholar
  23. 23.
    Hughes SA, Wedemeyer H, Harrison PM. Hepatitis delta virus. Lancet. 2011;378:73–85.PubMedCrossRefPubMedCentralGoogle Scholar
  24. 24.
    Gaeta GB, Stroffolini T, Chiaramonte M, Ascione T, Stornaiuolo G, Lobello S, Sagnelli E, et al. Chronic hepatitis D: a vanishing disease? An Italian multicenter study. Hepatology. 2000;32:824–7.PubMedCrossRefPubMedCentralGoogle Scholar
  25. 25.
    Cross TJ, Rizzi P, Horner M, Jolly A, Hussain MJ, Smith HM, Vergani D, et al. The increasing prevalence of hepatitis delta virus (HDV) infection in South London. J Med Virol. 2008;80:277–82.PubMedCrossRefPubMedCentralGoogle Scholar
  26. 26.
    Wedemeyer H, Heidrich B, Manns MP. Hepatitis D virus infection—not a vanishing disease in Europe! Hepatology. 2007;45:1331–2; author reply 1332–1333.PubMedCrossRefPubMedCentralGoogle Scholar
  27. 27.
    Borresen ML, Olsen OR, Ladefoged K, McMahon BJ, Hjuler T, Panum I, Simonetti J, et al. Hepatitis D outbreak among children in a hepatitis B hyper-endemic settlement in Greenland. J Viral Hepat. 2010;17:162–70.PubMedCrossRefPubMedCentralGoogle Scholar
  28. 28.
    Tsatsralt-Od B, Takahashi M, Endo K, Buyankhuu O, Baatarkhuu O, Nishizawa T, Okamoto H. Infection with hepatitis A, B, C, and delta viruses among patients with acute hepatitis in Mongolia. J Med Virol. 2006;78:542–50.PubMedCrossRefPubMedCentralGoogle Scholar
  29. 29.
    Gaeta GB, Stroffolini T, Smedile A, Niro G, Mele A. Hepatitis delta in Europe: vanishing or refreshing? Hepatology. 2007;46:1312–3.PubMedCrossRefPubMedCentralGoogle Scholar
  30. 30.
    Emerson SU, Purcell RH. Running like water—the omnipresence of hepatitis E. N Engl J Med. 2004;351:2367–8.PubMedCrossRefPubMedCentralGoogle Scholar
  31. 31.
    Stramer SL, Moritz ED, Foster GA, Ong E, Linnen JM, Hogema BM, Mak M, et al. Hepatitis E virus: seroprevalence and frequency of viral RNA detection among US blood donors. Transfusion. 2016;56:481–8.PubMedCrossRefPubMedCentralGoogle Scholar
  32. 32.
    Kuniholm MH, Purcell RH, McQuillan GM, Engle RE, Wasley A, Nelson KE. Epidemiology of hepatitis E virus in the United States: results from the Third National Health and Nutrition Examination Survey, 1988–1994. J Infect Dis. 2009;200:48–56.PubMedPubMedCentralCrossRefGoogle Scholar
  33. 33.
    Teshale EH, Denniston MM, Drobeniuc J, Kamili S, Teo CG, Holmberg SD. Decline in hepatitis E virus antibody prevalence in the United States from 1988–1994 to 2009–2010. J Infect Dis. 2015;211:366–73.PubMedCrossRefPubMedCentralGoogle Scholar
  34. 34.
    Niro GA, Ciancio A, Gaeta GB, Smedile A, Marrone A, Olivero A, Stanzione M, et al. Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta. Hepatology. 2006;44:713–20.PubMedCrossRefPubMedCentralGoogle Scholar
  35. 35.
    Castelnau C, Le Gal F, Ripault MP, Gordien E, Martinot-Peignoux M, Boyer N, Pham BN, et al. Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up. Hepatology. 2006;44:728–35.PubMedCrossRefPubMedCentralGoogle Scholar
  36. 36.
    Peron JM, Abravanel F, Guillaume M, Gerolami R, Nana J, Anty R, Pariente A, et al. Treatment of autochthonous acute hepatitis E with short-term ribavirin: a multicenter retrospective study. Liver Int. 2016;36:328–33.PubMedCrossRefPubMedCentralGoogle Scholar
  37. 37.
    Kamar N, Izopet J, Dalton HR. Chronic hepatitis e virus infection and treatment. J Clin Exp Hepatol. 2013;3:134–40.PubMedPubMedCentralCrossRefGoogle Scholar
  38. 38.
    I Mehrez M, Sa Fattah D, Aa Azeem N, A Saleh M, M Mostafa K. Hemochromatosis gene polymorphism as a predictor of sustained virological response to antiviral treatment in Egyptian chronic hepatitis C patients. Euroasian J Hepatogastroenterol. 2017;7:154–7.PubMedPubMedCentralCrossRefGoogle Scholar
  39. 39.
    Shrestha MP, Scott RM, Joshi DM, Mammen MP Jr, Thapa GB, Thapa N, Myint KS, et al. Safety and efficacy of a recombinant hepatitis E vaccine. N Engl J Med. 2007;356:895–903.PubMedCrossRefPubMedCentralGoogle Scholar
  40. 40.
    Zhu FC, Zhang J, Zhang XF, Zhou C, Wang ZZ, Huang SJ, Wang H, et al. Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial. Lancet. 2010;376:895–902.PubMedCrossRefPubMedCentralGoogle Scholar
  41. 41.
    Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2095–128.PubMedCrossRefPubMedCentralGoogle Scholar
  42. 42.
    Murray CJ, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, Ezzati M, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden Of Disease Study 2010. Lancet. 2012;380:2197–223.PubMedCrossRefPubMedCentralGoogle Scholar
  43. 43.
    Global Burden of Disease Study C. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;386:743–800.CrossRefGoogle Scholar
  44. 44.
    Collaborators GBDCoD. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390:1151–210.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Department of Medicine IIUniversity Hospital FreiburgFreiburgGermany

Personalised recommendations